4K-18-2 Ph2 PT2977 + Cabozantinib in Patients with Advanced Clear Cell RCC Kefauver/Santos
CTSU-EA8143 Ph 3 PROSPER RCC. Kefauver/Bsantos
CTSU-EA8134 Ph 3 Advanced Cancer Trial (InPact). Kefauver/Barg/Donaldson/Alexander
SWOG-S1500 PI1 Mult MET Kinase Inh. Kefauver/Bsantos
GU-Penis
GU-Prostate
4P-11-4 CTC Assessment: Prostate. Scott/Tran/Bsantos
4P-12-3 MDSC Assay: Ca Detection/ Monitoring. Karimi
4P-14-1 Ph II Phenelzine NRMPC. Kefauver/Barg/Bsantos
4P-14-6 Novel Biomarkers MRCP. Castellanos/Santos
4P-16-2 Enzalutamide or Radium223 Prostate Cancer Kefauver/Barg/Donaldson/Santos/Alexander
4P-16-3 18F-Fluorodeoxyglucose PET/CT FACIO/Vasquez-aldera/yasabal
4P-17-2 TRITON2, Ph2 Rucaparib in MRCP.
Kefauver/Santos/Scott(W)
4P-17-3 TRITON3, Ph3 Rucaparib vs Physician's Choice in mCRPC. Scott & Gilmore (W)
4P-17-4 Prostate Biomarkers for Repeat Ex. Ileana Aldana
4P-17-6 Ph3 GSK527562 + Androgen Deprivation Tx in CRPC. Kefauver/Santos/Scott(W)
4P-17-8 Metabolic profiling of PBCMs By LC-MS in prostate cancer. Gilmore/Scott/Cツ
4P-18-2 SIMCAP (Surgery in Metastatic Carcinoma of Prostate) Aldana/Borot/Rajanu/Kefauver
4P-19-5 Ph3/ Rand/DB Pembrolizumab+Docetaxel + Prednisone in mCRPC (MK-3475-921).GU Team/Kefauver/NB
4P-19-6 NRG-GU005 Ph3SIRT + SBRT vs IGRT & Hypofractionated IMRT in prostate cancer. Jhimlee/DeOliveira
NRG-GU006 Ph2 Salvage RadioTx+x/- Enhanced Anti-Androgen+Apal tamidine in RecPC Jhimlee/DeOliveira
RTOG-0924 Ph3 III Androgen Deprivation Tx + Radio Tx Prostate Ca. Jhimlee/DeOliveira
SWOG-S1802 Ph3 Rand SSTvs SST+ (surgery or Radiation) in mProstate Cancer. Barg/Donaldson/Santos/Tejada
4S-17-1 PhII of Retropertitoneal LN Dissection. I. aldana
CTSU-AGCT1531 Ph3 Caro vs. Cis for Standard Risk Peds/Adult in Germ Cell Tumors. GU Team/Kefauver/NB
CTSU-AGCT1532 (Norris only) Ph3 Rand acell vs stand BEPchemo in met.GMERCCL. GU Team/Kefauver
GU-Prostate
4T-14-1 PI Ph II Azacitidine + Entinostat NSCLC. Tse/DeOliveira
CTSU-A511216 Phase Clinical Trials. Mejia
5GYN-10-3 Tissue Banking - Gyne Surgeries. Alda
5GYN-15-0 Ph Il MRI of Retroperitoneal LN Dissection. I. Aldana
5GYN-15-1 PI PhIII MORA+003+Paci/PLD/OvCa Watkins/Facio
5GYN-15-2 Apixaban vs EnoxaparinWatkins/Facio
5GYN-16-1 PI Study of Oral Triapine + ChemoRad / LACC + Vultur. Casillas-Lopez/Cohen
5GYN-17-1 Ph3 Atezolizumab vs Placebo w/ paclitaxel, carbop, beva ovarian, fallopian /primary peritoneal cancer Watkins/Facio
5O-14-1 (SUSPENDED 4/29/16) Ph3 Masitinib+GemvssGem / Ovarian Watkins/Facio
5O-18-1 Ofranergene Obadenovec + Pacl+ vs. Pacl+ + Placebo Recur Platinum-Resistant Ovarian CA Facio/Casillas-Lopez/Cohen/Torres
GOG-0225 Diet + Physical Activity: Gyn Ca Modulation. Watkins-Facio
GYN-Uterus
5U-16-1 Endo & Obesity: Diet+Exercise Watkins/Facio
5U-18-1 Ph2 Rand Cabozantinib +Nivolumab in Endometrial Ca. Watkins/Facio
GYN-Vulva
NRG-GY006 Ph2 Radx+Cis Alone or in Combination with IVTriapine in Vaginal Cancer. Watkins/Facio
Head and Neck
7H-16-2 Toshiba HN CTP/Head & Neck. Carrasco
7H-17-1 Ph2 Efficacy/Safety of Autologous TIL (LN-145) in H&N CA. Tse/DeOliveira
7H-17-2 Ph3 Pembrol vs Neoadj Tx + SOC as Adjuvant Therapy for Stage III-IVA LA HNSCC Tse/DeOliveira
7H-18-1 Ph3 GC4419 to Reduce SOM Asso w/ ChemoradTx for Locally Advanced, NMH&N CA Tse/DeOliveira
7H-18-2 Ph2 AL101 (BMS-906024) in ACC Bearing Activating Notch Mutations Tse/DeOliveira
RTGO-1008 Chemotherapy/RT + RT Alone: SG. Jhimlee/DeOliveira
Lung
2L-15-1 Biospecimen Bank & Biomrkr/Lung Ca Bhushan/Diaz
2L-17-1 Liquid Biopsy Research Project. Mejia
2O-17-1 (SUSPENDED) Ph1 Olaparib+Cediranib/STx NCLC. Tse/deOliveira/jhimlee
CTSU-A151216 (TEMP ACCRUAL HOLD) Neoadjuvant Chemotherapy in Malignant Mesothelioma. Jhimlee/DeOliveira
Small Cell Lung
CTSU/NCI-CC003 Ph2/3 Prophy Cen Rad. Jhimlee/ DeOliveira
Non-Small Cell Lung
2N-13-6 Ph II Azacitidine + Entinostat NSCLC. Tse/DeOliveira
2N-15-6 (SUSPENDED) PhIII X-396 in Adv Solid Tumors & Exp In ALK+ NSCLC. Tse/DeOliveira
2N-16-9 RadioSx +/- TTFields for 1-10 brain mets. Leong
*2O-17-1 PhII-156: AZD9291+/- bevacizumab in EGRF mutant melanoma. Tse/Jhimlee/De Oliveira/Massopust (NB)
2O-17-2 Ph3 Atezolizumab or Placebo + Platinum based Chemotherapy in NSCLC. Tse/DeOliveira/Massopust (NB)
2N-17-2 Ph3 Atezolizumab or Placebo + Platinum based Chemotherapy in NSCLC. Tse/DeOliveira/Massopust (NB)
2N-17-3 (COHORT 2 CLOSED) Ph2 Pozotinib in NSCLC with EGF or HER2 Exon 20. Tse/Jhimlee
2N-19-1 (CANOPY-1) Facio/DeOliveira
2N-19-2 Ph3, Safety/Efficacy Stereotactic Body Radiot (SBRT) +/-Pembrolizumab (MK-3475) in nopeerable Stages II/II NSCLC (KEYNOTE-867). Tse/DeOliveira
CTSU-A081105 (11/02/15-Re-activated) Erlotinib/ Placebo/EGFR Mutant NSCLC Tse/DeOliveira (P)
CTSU-E4512 Ph3 Crizot vs Plic NSCLC. Tse/DeOliveira (P)
CTSU-A221504 Rand/placebo controlled oral Opioid Receptor Antagonist in NSCLC. Tse/DeOliveira
CTSU/NRG-LU002 PI/III Stereotactic Body RadTx. Jhimlee/DeOliveira
Melanoma
10M-17-4 Ph3 IMO-2125 + Ipil vs Ipil in Anti-PD-1 Refractory Melanoma. Jhimlee / Massopust (NB)
10M-18-2 PhII dabrafenib, trametinib, & navitox in BRAF mutant melanoma. Tse/Jhimlee/De Oliveira/ Massopust (NB)
CTSU-EA6174 Ph3 comparing MK-3475 (Pembrolizumab) to SOC in Merkel Cell Carcinoma. Rehman/Garcia/Oganesyan
SWOG-S1612 Ph1 PD-1 Blockade+MK-3475/Unresectable DM. Tse/DeOliveira
SWOG-S1607 Ph2 Talimogene Laherparepvec + MK-3475 in Adv Melanoma PD on Anti-PD/L1 Tx. Jhimlee/DeOliveira
SWOG-S1801 Ph2 adv vs neoadj MK-3475 for clinically detectable stage III-IV melanoma. Jhimlee/DeOliveira
Skin
Multiple Sites or Special Studies
0S-04-7 USC Tumor Bank/Casillas-Lopez/ Facio
0S-11-5 Circulating Tumor Cell Collection.
0S-12-3 (SUSPENDED 11/17/14)18F-FMAU Imaging in Ca Pts.
0S-12-4 Cancer Genetics Registry.Culver/Ricker
0S-15-5 LT Effect of TKI Ovarian Reserve & Fertility. Woo
0S-15-12 Norris Orien Total Cancer Care. Church
0S-15-7 (TEMPORARY SUSPENSION) PhII-159 Tamligene laherparepvec followed Talimogene laherparepvec + Nivolumab. Jhimlee/AlexanderP
0S-18-5 Improving Patient Access to Ca Clin Trials ( IMPACT Study). Nieves
0S-19-8 Precision Performance Status Assessment in Early Phase Clinical Trials. Mejia